WASHINGTON, Sept. 11, 2017 /PRNewswire/ -- A Trump administration agency proposal to cut Medicare drug payments to hospitals serving poor and rural Americans is counterproductive and would actually reduce access to care, a group of over 1,300 hospitals says in comments submitted today to the U.S. Department of Health and Human Services (HHS).
The proposal by the administration's Centers for Medicare & Medicaid Services (CMS) would slash payments to hospitals participating in a federal drug discount program called "340B." The program reduces drug costs for hospitals and other providers that serve a disproportionate share of low-income and rural patients. Hospitals use the savings from the program to waive co-pays and provide pharmaceuticals and other services at free or reduced cost to low-income and other vulnerable patients.
340B hospitals say CMS's proposal would undermine their ability to continue providing these services. Because the savings would be offset by increased Medicare spending for other services and higher beneficiary co-pays, the proposal would not reduce costs for Medicare or beneficiaries. Instead, it would increase costs for low-income patients by preventing hospitals from continuing to discount drugs and other services for patients in need. 340B Health pointed out that many of the Medicare patients served at their hospitals already get their co-pays waived.
"While we share the administration's concern about high drug prices, we don't believe that dramatically cutting payments to health care providers is the way to go," said Ted Slafsky, President and CEO of 340B Health, the trade group representing hospitals impacted by the regulation. "The administration intends for the proposal to be consumer friendly but the reality is that it will do nothing to reduce high drug prices or reduce costs for Medicare or seniors."
340B Health submitted the comments today strongly opposing the almost 30 percent proposed payment reduction targeting 340B hospitals issued by CMS in July. The proposed reduction would go into effect on Jan. 1, 2018.
Oncologists who serve high numbers of low-income patients are frightened by the proposal. "Simply put, HHS should not finalize its proposal to drastically cut Medicare Part B drug reimbursement to 340B hospitals because it would diminish our ability to serve our most vulnerable patient populations," said Dr. Robert Chapman, Head, Division of Hematology and Medical Oncology for the Henry Ford Health System in Detroit, Mich.
"The proposal would not lower costs for our patients, but would make it much more difficult for us to provide necessary cancer drugs to our patients who are insured by Medicare or Medicaid plans," added Dr. Scott Wegner, Medical Director for Cancer Services at Genesis Healthcare in Zanesville, Ohio. "The patients we serve here in Southeast Ohio rely on this program to offset the cost of cancer drugs, which are reimbursed by Medicaid and Medicare at rates that are actually lower than we pay to obtain the drugs. This proposal would directly jeopardize our ability to deliver cancer care to the more than two-thirds of our patients who are covered by Medicare or Medicaid."
"Our referral area includes five states in the intermountain region covering 17 percent of the continental U.S.," said Dr. John Sweetenham, Senior Director of Clinical Affairs and Executive Medical Director of Huntsman Cancer Institute in Salt Lake City, Utah. "University of Utah Health, of which we're part, provides $126 million in uncompensated care annually. We simply couldn't provide the same scope or level of care to those who need it if HHS follows through with this proposed cut."
340B Health cites a new survey highlighting how the proposed payment cut would affect patient care. Hospitals unanimously reported it would affect their ability to provide services to their low-income and rural patients. Eighty-six percent of hospitals said that the proposed rule would affect their ability to provide clinical services, especially infusion and oncology services to low-income patients.
Seventy-four percent said the cut would affect pharmacy services, more than two-thirds said the cut would affect their ability to provide uncompensated care, and nearly half said the cut would impact quality of care and patient outcomes.
"Our hospitals never turn away someone in need and neither should our leaders," said Slafsky. "This proposal would tear a large hole in America's healthcare safety net. We strongly urge HHS to drop it." In August, CMS's Medicare Advisory Panel on Hospital Outpatient Payments advised the agency to rescind the proposal.
340B Health is an association of more than 1,300 hospitals. We are the leading advocate and resource for hospitals that serve their communities through participation in the 340B drug pricing program. Learn more at www.340bhealth.org.
Contact: Tom Mirga
Office (202) 552-5853
Mobile (571) 213-9478
SOURCE 340B Health